▶ Watch on YouTube
Health

An experimental leukemia vaccine extends patients' survival in a phase 3 trial

2026-11-19 · Nuevo Día
An experimental leukemia vaccine extends patients' survival in a phase 3 trial

An experimental therapeutic vaccine for acute myeloid leukemia significantly extended patients' survival in a phase 3 clinical trial, biotechnology company SELLAS Life Sciences announced on November 17. The treatment, called galinpepimut-S (GPS), is not a preventive vaccine: it trains the immune system to attack leukemia cells that remain after chemotherapy.

In the REGAL trial, with 126 patients in second or later remission who could not receive a bone marrow transplant, median survival was 24 months with GPS versus 14.7 months with the best available treatment, a 41% reduction in the risk of death. The treatment was generally well tolerated, with mostly mild or moderate side effects, mainly local reactions at the injection site.

SELLAS plans to meet with the U.S. Food and Drug Administration (FDA) to discuss an accelerated path and to prepare its approval application during the first half of 2027. The results are preliminary and have not yet been peer reviewed or published in a scientific journal, so the treatment remains experimental and is not available to the public.

Photo: Cancer Network

Source: Cancer Network

← More news in Health · Leer en español